Not indicated for the preventive treatment of migraine.
- TRADE NAME: Reyvow (Eli Lilly and Co)
- INDICATIONS: Indicated for the acute treatment of migraine with or without aura in adults.
- CLASS: Serotonin type 1F receptor agonist
- HALF-LIFE: ~5.7 hours
- FDA APPROVAL DATE: 10/11/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CNS depressants, heart rate lowering drugs, P-gp or BCRP substrates, serotonergic drugs - PREGNANCY: There are no adequate data on the developmental risk associated with use in pregnant women.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see two reviews of lasmiditan in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/21/2024
